ClinicalTrials.gg
CompletedNCT01286818Updated Oct 6, 2014Results posted

A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)

A Phase 1 interventional study of Ramucirumab (IMC-1121B) and Irinotecan in Colorectal Carcinoma, sponsored by Eli Lilly and Company. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-10-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Colorectal Neoplasms by Eli Lilly and Company — 4 open to participants now, 7 under way, none of them phase 3. Colorectal Neoplasms · Eli Lilly and Company.

Enrollment
32nd of 34
6 · median 103
Started
2011
with 1 other
Phase 1
14 of 37
3 open now
Registered
21st of 37
by date

Among the 37 studies in Colorectal Neoplasms by Eli Lilly and Company, this one is the 32nd largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2011, is one of 14 in phase 1, and was the 21st registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 37 studies in Colorectal Neoplasms by Eli Lilly and Company are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Colorectal Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

The primary objective of this study is to investigate the safety and tolerability of the anti-vascular endothelial growth factor receptor-2 (anti-VEGFR-2) monoclonal antibody Ramucirumab (IMC-1121B) in combination with irinotecan, levofolinate, and 5-fluorouracil (FOLFIRI) in Japanese participants with advanced colorectal carcinoma (CRC).

03

Conditions studied

  • Colorectal Carcinoma

Keywords

  • Colon Cancer
  • Rectal Cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is Japanese
  • Has an (ECOG) performance status of 0 or 1
  • Has or cytologically confirmed CRC
  • Has disease that is not amenable to potentially curative resection
  • Has received no more than 2 prior systemic chemotherapy regimens in any setting (only 1 prior regimen for metastatic disease is permitted)
  • Has received combination therapy of bevacizumab, oxaliplatin, and a fluoropyrimidine for metastatic disease and has experienced disease progression during first-line therapy, or disease progression within 6 months after the last dose of first-line therapy, or discontinued part or all of first-line therapy due to toxicity and experienced disease progression within 6 months after the last dose of first-line therapy. Participants must have received a minimum of 2 doses of bevacizumab as part of a first-line regimen containing chemotherapy in order to enroll.
  • Has adequate hepatic, renal, hematologic, and coagulation function
  • The participant's urinary protein is ≤1+ on dipstick or routine urinalysis. If urine dipstick or routine analysis indicates proteinuria ≥2+, then a 24-hour urine must be collected and must demonstrate \<1000 milligrams (mg) of protein in 24 hours to allow participation in the study

Exclusion criteria

Exclusion Criteria:

  • Has received bevacizumab within 28 days prior to study registration
  • Has received chemotherapy within 21 days prior to study registration
  • Has received any previous systemic therapy (other than a combination of bevacizumab, oxaliplatin, and a fluoropyrimidine) for treatment of CRC
  • The participant experienced any of the following during first-line therapy with a bevacizumab-containing regimen: an arterial thrombotic/thromboembolic event; Grade 4 hypertension; Grade 4 proteinuria; a Grade 3-4 bleeding event; or bowel perforation
  • Has received wide-field (full-dose pelvic) radiotherapy within 28 days prior to study registration
  • Has undergone major surgery within 28 days or subcutaneous venous access device placement within 7 days prior to study registration
  • Has elective or planned surgery to be conducted during the trial
  • Has a history of deep vein thrombosis or pulmonary embolism within the past 12 months
  • Has experienced any arterial thrombotic event within the past 12 months
  • Participant is receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin, or similar agents
  • Participant is receiving chronic therapy with nonsteroidal anti-inflammatory agents [Aspirin up to 325 milligrams per day (mg/day) permitted]
  • Has a significant bleeding disorder or has had a significant (Grade 3 or higher) bleeding event within 3 months prior to registration date
  • Has a history of gastrointestinal perforation and/or fistulae within 6 months prior to registration date
  • Has symptomatic congestive heart failure, unstable angina pectoris, or symptomatic or poorly controlled cardiac arrhythmia
  • Has uncontrolled arterial hypertension despite standard medical management
  • Has a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to study registration
  • Has an acute/subacute bowel obstruction or history of chronic diarrhea
  • Has a history of inflammatory bowel disease or Crohn's disease requiring medical intervention within 12 months prior to registration date
  • The participant has either peptic ulcer disease associated with a bleeding event or known active diverticulitis
  • Has an active infection requiring antibiotic, antifungal, or antiviral therapy
  • Has known (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related illness
  • Has known or or uncontrolled spinal cord compression
  • Has a known history of Gilbert's Syndrome, or is known to have any of the following genotypes: uridine diphosphate glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1)*6/*6; UGT1A1*28/*28 or UGT1A1*6/*28
  • Has previous or concurrent , except for basal or squamous cell skin cancer and/or in situ carcinoma, or other solid tumors treated curatively and without evidence of recurrence for at least 3 years
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    FOLFIRI plus Ramucirumab (IMC-1121B)

    Biological: Ramucirumab (IMC-1121B) · Drug: Irinotecan · Drug: levofolinate · Drug: 5-Fluorouracil (5-FU)

Interventions

  • Ramucirumab (IMC-1121B): Intravenous (IV) infusions, 8 milligrams per kilogram (mg/kg) every 2 weeks

    Also known as: IMC-1121B, Ramucirumab, LY3009806

  • IV Infusion, 180 milligrams per square meter (mg/m²) every 2 weeks

  • IV infusion, 200 mg/m² every 2 weeks

  • 400 mg/m² bolus followed by a 2400 mg/m² continuous infusion, every 2 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants That Experienced Any Dose-Limiting Toxicities (DLT) During the DLT Assessment Period

    DLTs were adverse events (AEs) possibly related to study drug that met the National Cancer Institute's Common Terminology Criteria for AEs (NCI CTCAE, version 4.03): Grade 4 neutropenia ≥7 days or ≥Grade 3 with bacteremia or sepsis; Absolute neutrophil count \<1.0x10\^9/Liters with fever ≥38.3°Celsius requiring intravenous antibiotic therapy; Grade 4 thrombocytopenia or ≥Grade 3 with bleeding requiring platelet transfusion; ≥Grade 3 altered coagulation tests and no anticoagulation; ≥Grade 4 or uncontrolled hypertension; ≥Grade 3 non-hematologic toxicity (except non-clinically significant Grade 3 events like electrolyte abnormality, hypersensitivity, and arthralgia/myalgia); urine protein \>3 grams/24 hours; study drug-related toxicity causing Cycle 3, Day 1 treatment delay until Day 44 or later. Grade 3 or Grade 4 infusion-related reaction (hypersensitivity) due to ramucirumab or FOLFIRI, not a DLT.

    Time frame: Day 1, Cycle 1 through Day 1, Cycle 3 (1 cycle=14 days)

  2. Number of Participants With Ramucirumab Drug-Related Adverse Events or Serious Adverse Events

    Data are presented for the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade ≥3 TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered to be related to ramucirumab. Events related to Irinotecan, Levofolinate, and 5-fluorouracil (5-FU) were reported separately. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section.

    Time frame: Baseline to end of study (up to 49.3 weeks) plus 37 day follow-up

Secondary outcomes

  1. Number of Participants With Serum Anti-IMC-1121B Antibodies (Immunogenicity)

    Time frame: Day 1 of Cycle 5 (Week 9), Cycle 6 (Week 11), Cycle 7 (Week 13), and Cycle 9 (Week 17) [(1 cycle=14 days)]

  2. Maximum Concentration (Cmax) of Ramucirumab

    The Cmax of ramucirumab in serum on Day 1, Cycle 1 and on Day 1, Cycle 5, which was also considered Cmax at steady state (Cmax,ss), is reported.

    Time frame: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)

  3. Area Under the Curve (AUC) of Ramucirumab

    Reported for Day 1, Cycle 1 is AUC from time 0 extrapolated to infinity \[AUC(0-inf)\] and for Day 1, Cycle 5 is AUC over the dosing interval at steady state AUC(tau,ss).

    Time frame: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)

  4. Half Life (t1/2) of Ramucirumab

    t1/2 is the time required for the plasma/serum concentration to decrease 50%.

    Time frame: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)

  5. Clearance (CL) of Ramucirumab

    The total body CL of ramucirumab on Day 1, Cycle 1 and on Day 1, Cycle 5, which was also considered CL at steady state (CLss), is reported.

    Time frame: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)

  6. Steady State Volume of Distribution (Vss) of Ramucirumab

    Vss is the theoretical volume in which the total amount of study drug would need to be uniformly distributed during steady state to produce the same concentration as it is in plasma/serum.

    Time frame: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)

  7. Best Overall Response [Anti-Tumor Activity of FOLFIRI Plus Ramucirumab (IMC-1121B)]

    Best overall response evaluated using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) criteria. Complete Response (CR): disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to \<10 millimeters (mm). Partial Response (PR): at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter. Progressive Disease (PD): an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum on study (included baseline sum if that was the smallest on study). In addition, the sum must have demonstrated an absolute increase of at least 5 mm (the appearance of 1 or more new lesions was considered progression). Stable Disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started.

    Time frame: Every 8 weeks until PD (up to 49 weeks)

07

Results

Posted Oct 6, 2014

Participant flow

Participant flow — Overall Study
MilestoneFOLFIRI Plus Ramucirumab (IMC-1121B)
Started6
Completed dlt assessment period5
Completed6
Not completed0

Outcome measures

PrimaryNumber of Participants That Experienced Any Dose-Limiting Toxicities (DLT) During the DLT Assessment Period

DLTs were adverse events (AEs) possibly related to study drug that met the National Cancer Institute's Common Terminology Criteria for AEs (NCI CTCAE, version 4.03): Grade 4 neutropenia ≥7 days or ≥Grade 3 with bacteremia or sepsis; Absolute neutrophil count \<1.0x10\^9/Liters with fever ≥38.3°Celsius requiring intravenous antibiotic therapy; Grade 4 thrombocytopenia or ≥Grade 3 with bleeding requiring platelet transfusion; ≥Grade 3 altered coagulation tests and no anticoagulation; ≥Grade 4 or uncontrolled hypertension; ≥Grade 3 non-hematologic toxicity (except non-clinically significant Grade 3 events like electrolyte abnormality, hypersensitivity, and arthralgia/myalgia); urine protein \>3 grams/24 hours; study drug-related toxicity causing Cycle 3, Day 1 treatment delay until Day 44 or later. Grade 3 or Grade 4 infusion-related reaction (hypersensitivity) due to ramucirumab or FOLFIRI, not a DLT.

Time frame:
Day 1, Cycle 1 through Day 1, Cycle 3 (1 cycle=14 days)
Reported as:
Number · participants
Number of Participants That Experienced Any Dose-Limiting Toxicities (DLT) During the DLT Assessment Period
participantsFOLFIRI Plus Ramucirumab (IMC-1121B)
Number of Participants That Experienced Any Dose-Limiting Toxicities (DLT) During the DLT Assessment Period1
PrimaryNumber of Participants With Ramucirumab Drug-Related Adverse Events or Serious Adverse Events

Data are presented for the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade ≥3 TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered to be related to ramucirumab. Events related to Irinotecan, Levofolinate, and 5-fluorouracil (5-FU) were reported separately. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section.

Time frame:
Baseline to end of study (up to 49.3 weeks) plus 37 day follow-up
Reported as:
Number · participants
Number of Participants With Ramucirumab Drug-Related Adverse Events or Serious Adverse Events
participantsFOLFIRI Plus Ramucirumab (IMC-1121B)
Related TEAE6
Related SAE0
Related Grade ≥3 TEAE3
Related AE leading to discontinuation2
SecondaryNumber of Participants With Serum Anti-IMC-1121B Antibodies (Immunogenicity)
Time frame:
Day 1 of Cycle 5 (Week 9), Cycle 6 (Week 11), Cycle 7 (Week 13), and Cycle 9 (Week 17) [(1 cycle=14 days)]
Reported as:
Number · participants
Number of Participants With Serum Anti-IMC-1121B Antibodies (Immunogenicity)
participantsFOLFIRI Plus Ramucirumab (IMC-1121B)
Day 1, Cycle 5 (n=5)0
Day 1, Cycle 6 (n=1)0
Day 1, Cycle 7 (n=3)0
Day 1, Cycle 9 (n=4)0
SecondaryMaximum Concentration (Cmax) of Ramucirumab

The Cmax of ramucirumab in serum on Day 1, Cycle 1 and on Day 1, Cycle 5, which was also considered Cmax at steady state (Cmax,ss), is reported.

Time frame:
Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
Reported as:
Geometric mean · micrograms per milliliter (mcg/mL)
Maximum Concentration (Cmax) of Ramucirumab
micrograms per milliliter (mcg/mL)FOLFIRI Plus Ramucirumab (IMC-1121B)
Day 1, Cycle 1 (n=6)245 ± 6
Day 1, Cycle 5 (n=2)267 ± 11
SecondaryArea Under the Curve (AUC) of Ramucirumab

Reported for Day 1, Cycle 1 is AUC from time 0 extrapolated to infinity \[AUC(0-inf)\] and for Day 1, Cycle 5 is AUC over the dosing interval at steady state AUC(tau,ss).

Time frame:
Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
Reported as:
Geometric mean · micrograms*day/milliliter (mcg*day/mL)
Area Under the Curve (AUC) of Ramucirumab
micrograms*day/milliliter (mcg*day/mL)FOLFIRI Plus Ramucirumab (IMC-1121B)
Day 1, Cycle 1 (n=4)1600 ± 15
Day 1, Cycle 5 (n=2)1690 ± 38
SecondaryHalf Life (t1/2) of Ramucirumab

t1/2 is the time required for the plasma/serum concentration to decrease 50%.

Time frame:
Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
Reported as:
Geometric mean · days
Half Life (t1/2) of Ramucirumab
daysFOLFIRI Plus Ramucirumab (IMC-1121B)
Day 1, Cycle 1 (n=6)7.38 ± 19
Day 1, Cycle 5 (n=2)8.55 ± 2
SecondaryClearance (CL) of Ramucirumab

The total body CL of ramucirumab on Day 1, Cycle 1 and on Day 1, Cycle 5, which was also considered CL at steady state (CLss), is reported.

Time frame:
Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
Reported as:
Geometric mean · milliliters per hour (mL/hr)
Clearance (CL) of Ramucirumab
milliliters per hour (mL/hr)FOLFIRI Plus Ramucirumab (IMC-1121B)
Day 1, Cycle 1 (n=4)11.4 ± 26
Day 1, Cycle 5 (n=2)10.4 ± 61
SecondarySteady State Volume of Distribution (Vss) of Ramucirumab

Vss is the theoretical volume in which the total amount of study drug would need to be uniformly distributed during steady state to produce the same concentration as it is in plasma/serum.

Time frame:
Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
Reported as:
Geometric mean · Liters (L)
Steady State Volume of Distribution (Vss) of Ramucirumab
Liters (L)FOLFIRI Plus Ramucirumab (IMC-1121B)
Day 1, Cycle 1 (n=4)2.51 ± 25
Day 1, Cycle 5 (n=2)3.06 ± 56
SecondaryBest Overall Response [Anti-Tumor Activity of FOLFIRI Plus Ramucirumab (IMC-1121B)]

Best overall response evaluated using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) criteria. Complete Response (CR): disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to \<10 millimeters (mm). Partial Response (PR): at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter. Progressive Disease (PD): an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum on study (included baseline sum if that was the smallest on study). In addition, the sum must have demonstrated an absolute increase of at least 5 mm (the appearance of 1 or more new lesions was considered progression). Stable Disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started.

Time frame:
Every 8 weeks until PD (up to 49 weeks)
Reported as:
Number · participants
Best Overall Response [Anti-Tumor Activity of FOLFIRI Plus Ramucirumab (IMC-1121B)]
participantsFOLFIRI Plus Ramucirumab (IMC-1121B)
Complete Response (CR)0
Partial Response (PR)1
Stable Disease (SD)4
Progressive Disease (PD)1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FOLFIRI Plus Ramucirumab (IMC-1121B)—0/6 (0%)6/6 (100%)
Most frequent other events
Showing 10 of 50
Most frequent other events
EventFOLFIRI Plus Ramucirumab (IMC-1121B)
NEUTROPENIABlood and lymphatic system disorders5/6
DIARRHOEAGastrointestinal disorders5/6
STOMATITISGastrointestinal disorders5/6
THROMBOCYTOPENIABlood and lymphatic system disorders4/6
VOMITINGGastrointestinal disorders4/6
DECREASED APPETITEMetabolism and nutrition disorders4/6
NAUSEAGastrointestinal disorders3/6
FATIGUEGeneral disorders3/6
UTERINE HAEMORRHAGEReproductive system and breast disorders1/2
EPISTAXISRespiratory, thoracic and mediastinal disorders3/6

Baseline characteristics

Safety population: Participants who received any quantity of study medication.

Age, Categorical
Age, Categorical(Participants)FOLFIRI Plus Ramucirumab (IMC-1121B)
<=18 years0
Between 18 and 65 years4
>=65 years2
Sex: Female, Male
Sex: Female, Male(Participants)FOLFIRI Plus Ramucirumab (IMC-1121B)
Female2
Male4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)FOLFIRI Plus Ramucirumab (IMC-1121B)
Asian6
Region of Enrollment
Region of Enrollment(participants)FOLFIRI Plus Ramucirumab (IMC-1121B)
Japan6
Eastern Cooperative Oncology Group (ECOG) performance status
Eastern Cooperative Oncology Group (ECOG) performance status(participants)FOLFIRI Plus Ramucirumab (IMC-1121B)
0 - Fully active3
1 - Ambulatory, restricted strenuous activity3
08

Study locations

3 sites
  • ImClone Investigational Site
    Chiba, 277-8577, Japan
  • ImClone Investigational Site
    Osaka, 569-8686, Japan
  • ImClone Investigational Site
    Shizuoka, 411-8777, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Feb 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2011
First posted
Jan 31, 2011
Start
Feb 2011
Primary completionActual
Feb 2012
CompletionActual
Mar 2012
Results first posted
Oct 6, 2014
Last update
Oct 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01286818
Responsible party
Sponsor
First posted
Jan 31, 2011
Start date
Feb 2011
Primary completion
Feb 2012
Completion
Mar 2012
Results posted
Oct 6, 2014
Last update
Oct 6, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion